Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Ohe, Yuichiro; Ohashi, Yasuo; Kubota, Keiichi; Tamura, Tomohide; Nakagawa, Kazuhiko; Negoro, Shunichi; Nishiwaki, Yutaka; Saijo, Nagahiro; Ariyoshi, Y; Fukuoka, Masahiro

doi:10.1093/annonc/mdl377

Cited by 558 publications

(478 citation statements)

References 24 publications

Supporting

Mentioning

442

Contrasting

Unclassified

Order By: Relevance

“…Because the standard treatment for patients with stage IIIB with malignant effusion or stage IV is platinum and third generation doublet chemotherapy, patients with high expression of ERCC1 might benefit from alternative platinum non-containing regimens such as third generation doublets. However, a confirmatory study is essential to prove this speculation [1,[3][4][5][6].…”

Section: Discussionmentioning

confidence: 99%

“…Palliative chemotherapy with doublet regimens using platinum and third-generation agents such as taxanes and gemcitabine is the standard of care in patients with metastatic or recurrent disease, with some improvement in survival and quality of life [1,[3][4][5][6]. Despite advances in palliative chemotherapy, however, the outcome of advanced NSCLC is still very poor, with a median survival of 8-12 months [1,[3][4][5][6]. Therefore, determining parameters to identify patients who would benefit from a specific chemotherapy regimen, and those who would not, has strong clinical implications.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy

et al. 2009

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy

et al. 2009

View full text Add to dashboard Cite

“…In the study by Schiller et al [22] cisplatin-gemcitabine was compared with both cisplatin-paclitaxel and carboplatin-paclitaxel, and with cisplatin-vinorelbine; in the same way cisplatin-vinorelbine was compared with cisplatin-paclitaxel and with carboplatinpaclitaxel. The same approach was adopted when analyzing the studies by Fossella et al [24], Smit et al [25], Treat et al [43], Liu et al [57], and Ohe et al [66].…”

Section: Identification Of Trialsmentioning

confidence: 99%

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Grossi¹,

Aita²,

Defferrari³

et al. 2009

The Oncologist

View full text Add to dashboard Cite

Background. The therapeutic equivalence of different third-generation agents in the first-line treatment of advanced non-small cell lung cancer (NSCLC) has long been accepted, although recent studies seem to suggest some superiority of gemcitabine-or docetaxel-containing regimens over other third-generation doublets.Objective. To assess the relative impact of different third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer by considering both response and progressive disease (PD) rates as outcome measures.Methods. Published and unpublished data were collected from randomized trials comparing a gemcitabine-, docetaxel-, vinorelbine-or paclitaxel-containing regimen with one or more gemcitabine-, docetaxel-, vinorelbine-or paclitaxel-free combinations. For

show abstract

“…1,2 Further molecular investigation of lung cancer is required to develop new treatment strategies and improve patients' prognoses.…”

Section: Introductionmentioning

confidence: 99%

Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma

Tomonaga

Nakamura

Yamaguchi

et al. 2013

Clinical Lung Cancer

View full text Add to dashboard Cite

2 Micro abstractIntra-tumor heterogeneity of epidermal growth factor receptor (EGFR) mutations in patients with mixed-type lung adenocarcinoma was analyzed according to histological patterns. Intra-tumor heterogeneity of EGFR mutations was detected in 9 of 38 tumors, and there was a significant correlation between heterogeneity of EGFR mutations and smoking history (P<0.043). Clinical Practice Points• EGFR mutations are factors predictive of response to EGFR-TKI treatment. However, lung cancer is thought to be the result of the accumulation of genetic alterations over a long course of exposure to a carcinogen, and the existence of intra-tumor heterogeneity of EGFR mutations remains unclear. Thus, the existence of intra-tumor heterogeneity was analyzed in patients with mixed-type lung adenocarcinoma according to histological patterns.• Intra-tumor heterogeneity of EGFR mutations was detected in 9 of 38 tumors, and a significant correlation between heterogeneity of EGFR 3 mutations and smoking history was found.• Response to EGFR-TKIs might be partial and insufficient in tumors having intra-tumor heterogeneity of EGFR mutations. New treatment strategies for patients with lung adenocarcinoma harboring heterogeneous EGFR mutations are needed.

show abstract

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Abstract: The four regimens have similar efficacy and different toxicity profiles, and they can be used to treat advanced NSCLC patients.

Cited by 558 publications

References 24 publications

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma

Contact Info

Product

Resources

About